DDInter856 DDInter1945
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Vorapaxar {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hemin
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Chamomile
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Vorapaxar may lead to a major life threatening interaction when taken with Anagrelide
Vorapaxar may lead to a major life threatening interaction when taken with Troleandomycin